forecast glp-1 prescriptions growth 2025 semaglutide tirzepatide Monitoring Report: RA Prescribing Trends – September Data GLP-1 Nutritional Support Market Size

Currently, the FDA has officially approved a higher-dose formulation of semaglutide called Wegovy specifically for chronic weight management in adults who are overweight or obese, even if they do not have diabetes

TEXT ON-SCREEN: PREP, CHECK, SELECT, INJECT

Much needed Lost 27lbs so far

Pancreatitis Warning: Patients should discontinue use if pancreatitis is suspected

Several observational studies have reported greater 12-month weight loss with tirzepatide than semaglutide approved for the treatment of type 2 diabetes, but differences in follow-up duration, dosing, and adherence limit comparability with shorter-term outcomes [12, 13]